Department of Diagnostic Imaging, Baltimore VA Medical Center, Baltimore, Maryland 21201, USA.
J Am Coll Radiol. 2010;7(2):120-4. doi: 10.1016/j.jacr.2009.09.018.
The Institute of Medicine has determined that adverse drug events (ADEs) are the number one cause of medical errors in the United States and that additional efforts are required to improve patient safety. Medical imaging plays an important role in ADEs, most commonly related to the administration of imaging contrast agents. For medical imaging providers to assume a proactive role in patient safety, the creation of objective, data-driven quality metrics is advocated, which analyze all steps in the drug delivery chain, including procurement, prescription, dispersal, administration, monitoring, and management. These metrics would lead to the creation of a quality scorecard, developed to create objective accountability measures for all actors involved in this chain of events, including pharmacists, radiologists, clinicians, physicists, technologists, administrators, nurses, vendors, and patients. The ultimate goal of such an endeavor is to improve patient safety through the reduction of ADEs and the creation and refinement of data-driven best-practice guidelines.
美国医学研究所已确定，药物不良反应（ADE）是美国医疗差错的首要原因，需要进一步努力提高患者安全。医学影像在 ADE 中起着重要作用，最常见的是与影像对比剂的给药有关。为了使医学影像提供者在患者安全方面发挥积极主动的作用，提倡创建客观的、基于数据的质量指标，对药物输送链中的所有步骤进行分析，包括采购、处方、分发、给药、监测和管理。这些指标将导致创建一个质量记分卡，旨在为涉及该事件链的所有参与者（包括药剂师、放射科医生、临床医生、物理学家、技术人员、管理人员、护士、供应商和患者）创建客观的问责措施。这一努力的最终目标是通过减少 ADE 并创建和完善基于数据的最佳实践指南来提高患者安全。
